Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gamida Cell Ltd. - Ordinary Shares (NQ:GMDA)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gamida Cell Ltd. - Ordinary Shares

< Previous 1 2 3 Next >
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
Appoints Abigail “Abbey” Jenkins, a veteran biotech executive with over 20 years of experience in commercial leadership, to Board of Directors 
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Gamida Cell Reports Preliminary Data from Phase 1 Study of Natural Killer (NK) Cell Therapy Candidate GDA-201
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Issues Update on Israel Operations
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell to Present Corporate Highlights at 2023 Cell & Gene Meeting on the Mesa
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell to Present at Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting
From Gamida Cell Ltd.
Via Business Wire
First Patient Receives Gamida Cell's Omisirge™ (omidubicel-onlv)
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell to Present Corporate Highlights at the H.C. Wainwright 25th Annual Global Investment Conference
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Reports Second Quarter and First Half 2023 Financial Results and Provides Company Update
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell to Report Second Quarter 2023 Financial Results
From Gamida Cell Ltd.
Via Business Wire
Data Published in Transplantation and Cellular Therapy Suggest Antiviral Protection After Transplantation with Gamida Cell’s Omisirge® (omidubicel-onlv)
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference
From Gamida Cell Ltd.
Via Business Wire
Data To Be Presented on Gamida Cell Natural Killer (NK) Cell Therapy Candidate GDA-201 at the International Society for Cell & Gene Therapy 2023 Annual Meeting
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Appoints Terry Coelho as CFO
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Reports First Quarter 2023 Financial Results and Provides Company Update
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Announces the Date of Its First Quarter 2023 Financial Results and Webcast
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Announces Pricing of $23 Million Public Offering of Securities
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Announces Launch of Public Offering of Securities
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Stock Jumps Over 100% on FDA Approval
Gamida Cell Ltd. (NASDAQ: GMDA) is an Israeli-based developmental biotechnology company specializing in discovering and advancing cell therapies to fight bloo 
Via MarketBeat
Gamida Cell (NASDAQ: GMDA) Announces its Omisirge Allogeneic Cell Therapy Receives FDA Approval
Gamida Cell Ltd. (NASDAQ: GMDA) is a biopharma company that is focused on utilizing cell therapy to create innovative therapeutics. 
Via Spotlight Growth
Promising Upsides on these Biotech Penny Stocks
These three biotech stocks each have a consensus Buy rating. While they are down from historic highs, impressive upsides make them worth consideration. 
Via MarketBeat
Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Reports Full Year 2022 Financial Results and Provides Company Update
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Announces Changes to Board of Directors
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Announces the Date of Its Fourth Quarter and Full Year 2022 Financial Results and Webcast
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell to Present Corporate Highlights at the Oppenheimer 33rd Annual Healthcare Conference
From Gamida Cell Ltd.
Via Business Wire
Data Presented on Gamida Cell’s Omidubicel, GDA-201 at the 2023 Tandem Meetings of ASTCT and CIBMTR
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Announces Closing of $25 Million Financing With Highbridge
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Provides Regulatory Update on Omidubicel
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Reports Third Quarter 2022 Financial Results and Provides Company Update
From Gamida Cell Ltd.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.